Application of triptolide in preparation of ubiquitin-binding enzyme UBE2N inhibitor
Through the targeted binding of triptylusine to the ubiquitin-binding enzyme UBE2N, the catalytic activity is inhibited, and the problems of chemotherapy resistance and metastasis of lung cancer are solved, and a new lung cancer treatment strategy is provided, which significantly improves the therapeutic effect.
Patent Information
- Application Number
- CN202411403276.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-09
- Publication Date
- 2024-12-03
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The prior art has failed to effectively utilize the application of triptyrosine in inhibiting the ubiquitin-binding enzyme UBE2N, making it difficult to solve the chemotherapy resistance and metastasis of lung cancer.
Tributycin or its derivatives are used as inhibitors of the ubiquitin-binding enzyme UBE2N, and its catalytic activity is inhibited by targeted binding to the UBE2N protein, thereby developing new drugs for the treatment of lung cancer.
Tributycin significantly improves the thermal stability of UBE2N protein and effectively inhibits the metastasis and chemotherapy resistance of lung cancer cells in in vitro and in vivo experiments, providing a new strategy for lung cancer treatment.
Smart Images

Figure CN119055646A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biomedicine, provides a new use of tripterygium wilfordii alkaloids, and specifically relates to the use of tripterygium wilfordii alkaloids in the preparation of ubiquitin-binding enzyme UBE2N inhibitors. Background Art
[0002] Lung cancer is one of the most common malignant tumors. Statistics show that the incidence and mortality of lung cancer rank first worldwide, seriously threatening human life and health. However, the cause of lung cancer is still not completely clear. A large amount of data shows that the risk factors of lung cancer include smoking (including secondhand smoke), asbestos, radon, arsenic, ionizing radiation, halogenated olefins, polycyclic aromatic compounds, nickel, etc. The treatment methods of lung cancer include: surgical treatment and drug treatment. Among them, surgical treatment includes surgical resection of the lungs, but when too much lung tissue is resected, it will have a certain impact on the patient's postoperative survival. Drug treatment mainly includes chemotherapy and biological targeted drug therapy. Long-term chemotherapy is prone to drug resistance, which reduces the treatment effect. There are many types of biological targeted drug therapy drugs, but tumor cell gene target detection is required. Moreover, in the treatment of lung cancer, chemotherapy resistance and metastasis are one of the main reasons for its treatment failure. Therefore, in-depth exploration of the molecular mechanism of chemotherapy resistance and metastasis of lung cancer and finding effective therapeutic targets have become clinical problems that need to be solved urgently. Studies have shown that the ubiquitin-binding enzyme UBE2N plays an important role in the progression of lung cancer. Therefore, developing inhibitors of UBE2N and using it as a new target can provide new strategies for the treatment of lung cancer.
[0003] Wilforine is a natural extract compound, mainly derived from Tripterygium wilfordii, a plant of the genus Tripterygium wilfordii of the Celastraceae family. It is a sesquiterpenoid macrolide alkaloid and one of the Tripterygium wilfordii alkaloids. Studies have shown that Tripterygium wilfordii alkaloids are generally effective in treating rheumatoid arthritis, but there are no reports on the effect of Wilforine in inhibiting the ubiquitin-binding enzyme UBE2N. Summary of the invention
[0004] In order to solve the defect that there is no report on the use of tripterygium wilfordii in inhibiting the ubiquitin-binding enzyme UBE2N in the prior art, the present invention provides a new use of tripterygium wilfordii, specifically relates to the use of tripterygium wilfordii in preparing an inhibitor of the ubiquitin-binding enzyme UBE2N, and further to the use of tripterygium wilfordii in inhibiting chemotherapy resistance and metastasis of lung cancer.
[0005] In order to solve the above technical problems, the present invention adopts the following technical solutions.
[0006] The present invention provides the use of triptolide or its derivatives in preparing an inhibitor of ubiquitin-binding enzyme UBE2N.
[0007] In the present invention, the derivatives include structural analogs and salts of tripterygium wilfordii.
[0008] The present invention also provides an inhibitor of ubiquitin-binding enzyme UBE2N, which uses the tripterygium wilfordii alkaloid or its derivatives as the only effective ingredient.
[0009] Some technical solutions of the present invention also include: pharmaceutically acceptable excipients.
[0010] In some technical solutions of the present invention, the content of the drug is 1w% to 99w%.
[0011] In some embodiments of the present invention, the excipient is selected from one or more of solvents, propellants, solubilizers, cosolvents, emulsifiers, colorants, adhesives, disintegrants, fillers, lubricants, wetting agents, osmotic pressure regulators, stabilizers, glidants, flavoring agents, preservatives, suspending agents, coating materials, fragrances, anti-adhesives, integrities, penetration enhancers, pH regulators, buffers, plasticizers, surfactants, foaming agents, defoamers, thickeners, inclusion agents, humectants, absorbents, diluents, flocculants and deflocculating agents, filter aids and release retardants.
[0012] In some embodiments of the present invention, the filler is selected from starch, sucrose, lactose or microcrystalline cellulose; the binder is selected from cellulose derivatives, alginate, gelatin or polyvinyl pyrrolidone; the wetting agent is selected from water, glycerol, ethanol, methylcellulose, sodium carboxymethyl cellulose, low-substituted hydroxypropyl cellulose or hydroxypropyl methylcellulose; the disintegrant is selected from sodium carboxymethyl starch, hydroxypropyl cellulose, cross-linked carboxymethyl cellulose, agar, calcium carbonate or sodium bicarbonate; the absorption promoter is a quaternary ammonium compound; the surfactant is selected from cetyl alcohol or sodium lauryl sulfate; the adsorption carrier is selected from kaolin or bentonite; the lubricant is selected from talc, calcium and magnesium stearate, micropowder silica gel or polyethylene glycol; the flavoring agent is selected from sucrose, monosyrup, aromatic syrup, glycerol, sorbitol or mannitol.
[0013] The present invention also provides the use of the inhibitor of the ubiquitin-binding enzyme UBE2N in preparing a medicine for treating lung cancer.
[0014] In some technical solutions of the present invention, the drug is used to inhibit the metastasis of lung cancer cells.
[0015] In some technical solutions of the present invention, the drug is used to promote the sensitivity of lung cancer resistant cells to platinum chemotherapy drugs.
[0016] In some technical solutions of the present invention, the platinum chemotherapy drug includes cisplatin.
[0017] The present invention also provides a medicine for treating lung cancer, comprising the inhibitor of the ubiquitin-binding enzyme UBE2N.
[0018] In some technical solutions of the present invention, the lung cancer includes squamous cell lung carcinoma, small cell lung cancer, adenocarcinoma, adenosquamous lung carcinoma and carcinoid lung.
[0019] Compared with the prior art, the present invention has the following beneficial effects:
[0020] In the present invention, through MOE molecular docking software analysis, it is found that tripterygium alkaloids can target and bind to UBE2N protein, and its binding sites are Asp81, Cys87 and Asp124 amino acid residues. Through cell heat transfer experiments, tripterygium alkaloids significantly improve the thermal stability of UBE2N protein, indicating that tripterygium alkaloids target and bind to UBE2N protein. Through in vitro ubiquitination experiments, it is verified that tripterygium alkaloids can significantly inhibit the catalytic activity of UBE2N protein, providing a strategy for the preparation of UBE2N inhibitors and providing a new use for tripterygium alkaloids.
[0021] In the present invention, tripterygium wilfordii alkaloids are used to act on lung cancer cells, and the result shows that tripterygium wilfordii alkaloids can inhibit the chemotherapy resistance and metastasis of lung cancer, thus providing a new drug for the treatment of lung cancer. BRIEF DESCRIPTION OF THE DRAWINGS
[0022] Figure 1 This is the molecular structure of Wilforine.
[0023] Figure 2 The binding pattern diagram of triptolide and ubiquitin-binding enzyme UBE2N protein analyzed by MOE software.
[0024] Figure 3 Schematic diagram of the binding interaction between triptolide and UBE2N protein analyzed by cell thermal shift assay (CETSA).
[0025] Figure 4 This is a diagram showing the results of analyzing the inhibitory effect of triptolide on UBE2N activity through an in vitro ubiquitination experiment.
[0026] Figure 5 This is a graph showing the results of analyzing the ability of tripterygium wilfordii alkaloids to inhibit lung cancer chemotherapy resistance in vitro through IC50 experiments.
[0027] Figure 6 This figure shows the results of analyzing the effect of tripterygium wilfordii alkaloids in inhibiting lung cancer chemotherapy resistance in vivo using a nude mouse xenograft tumor model.
[0028] Figure 7 This is a diagram showing the results of a Transwell experiment analyzing the ability of tripterygium wilfordii alkaloids to inhibit lung cancer metastasis in vitro.
[0029] Figure 8 This is a diagram showing the results of analyzing the inhibitory effect of tripterygium wilfordii alkaloids on lung cancer metastasis in vivo in a nude mouse xenograft tumor model. DETAILED DESCRIPTION
[0030] The present invention is described in detail below in conjunction with specific examples, but it should not be construed as limiting the present invention. Unless otherwise specified, the technical means used in the following examples are conventional means well known to those skilled in the art, and the materials, reagents, etc. used in the following examples, unless otherwise specified, can be obtained from commercial sources.
[0031] Lung cancer is one of the most common malignant tumors. Statistics show that the incidence and mortality of lung cancer rank first worldwide, seriously threatening human life and health. However, the cause of lung cancer is still not completely clear. A large amount of data shows that the risk factors of lung cancer include smoking (including secondhand smoke), asbestos, radon, arsenic, ionizing radiation, halogenated olefins, polycyclic aromatic compounds, nickel, etc. Treatment methods for lung cancer include: surgical treatment and drug treatment. Among them, surgical treatment includes surgical resection of the lungs, but when too much lung tissue is resected, it will have a certain impact on the patient's postoperative survival. Drug treatment mainly includes chemotherapy and biological targeted drug therapy. Long-term chemotherapy is prone to drug resistance, which reduces the treatment effect. There are many types of biological targeted drug therapy, but it is necessary to do gene target detection of tumor cells. Moreover, in the treatment of lung cancer, chemotherapy resistance and metastasis are one of the main reasons for its treatment failure. Therefore, in-depth exploration of the molecular mechanism of chemotherapy resistance and metastasis of lung cancer and finding effective therapeutic targets have become clinical problems that need to be solved urgently.
[0032] Wilforine is a natural extract compound, mainly derived from Tripterygium wilfordii, a plant of the Celastraceae family. It belongs to the sesquiterpenoid macrolide alkaloids and is one of the Tripterygium wilfordii alkaloids. Studies have shown that Tripterygium wilfordii alkaloids are generally effective in the treatment of rheumatoid arthritis, but there are no reports on the use of Wilforine in inhibiting the ubiquitin-binding enzyme UBE2N and treating lung cancer.
[0033] The present invention provides the use of tripterygium wilfordii alkaloids in the preparation of inhibitors of ubiquitin-binding enzyme UBE2N. In the present invention, MOE molecular docking software is used to prove that tripterygium wilfordii alkaloids can be targeted and bound to UBE2N protein, and then a cell thermal transfer assay (CETSA) is used to prove that tripterygium wilfordii alkaloids inhibit UBE2N protein degradation and significantly improve the thermal stability of UBE2N protein. Then, an in vitro ubiquitination experiment is used to prove that tripterygium wilfordii alkaloids can inhibit the catalytic activity of UBE2N protein. The present invention provides a new use of tripterygium wilfordii alkaloids.
[0034] The present invention also provides a drug for treating lung cancer, comprising: the inhibitor of the ubiquitin-binding enzyme UBE2N and a platinum-based chemotherapy drug. In the present invention, cell experiments and in vivo experiments in mice have proven that the drug can be used to inhibit lung cancer cell metastasis and promote the sensitivity of lung cancer-resistant cells to platinum-based chemotherapy drugs, providing a new idea for the treatment of lung cancer.
[0035] Embodiment 1:
[0036] Wilforine (purchased from Selleck.cn, catalog number S0921) targets and binds to the ubiquitin-binding enzyme UBE2N (UBE2N) protein
[0037] (1) MOE molecular docking software was used to analyze the binding interaction between tripterygium wilfordii alkaloids and UBE2N protein.
[0038] The molecular structure of tripterygium wilfordii alkaloids is shown in the figure Figure 1 The molecular docking results are shown in Figure 2 As shown, the MOE software docking results showed that triptolide could target and bind to the UBE2N protein, and its binding sites were Asp81, Cys87 and Asp124 amino acid residues.
[0039] (2) Cellular thermal shift assay (CETSA) to detect the binding of triptolide to UBE2N protein
[0040] ① Cell plating: When A549 cells are in good condition, discard the old RPMI-1640 medium (purchased from Wuhan Saiweier Biotechnology Co., Ltd., catalog number: G4531-500ML), wash the cells once with PBS solution, add 500 μL of trypsin to digest the cells; after the cells are digested, spread 6.0×10 6 The cells were placed in a cell culture incubator containing 5% CO2 and cultured overnight at 37°C.
[0041] ②Drug treatment: discard the old culture medium in the culture dish, add 8mL of fresh RPMI-1640 complete culture medium (Wuhan Sevier Biotechnology Co., Ltd., catalog number: G4531-500ML), add 500μM triptolide to the experimental group, and add an equal volume of control solvent DMSO to the control group, and culture in a 37℃ cell culture incubator containing 5% CO2 for 3h.
[0042] ③ After 3 hours of drug treatment, discard the old culture medium, wash the cells with PBS buffer, add 500 μL of trypsin to digest the cells, and after the cell digestion is complete, add 1 mL of RPMI-1640 complete culture medium to neutralize the trypsin. Use a pipette to gently blow the cell suspension evenly, transfer it to a new sterile EP tube, place it in a centrifuge, and centrifuge it at 1800 rpm for 3 minutes; discard the supernatant and add PBS buffer to wash the cell pellet once.
[0043] ④ Resuspend the cell pellet with PBS buffer containing 1mM protease and 1mM protein phosphatase inhibitor, divide the cell suspension into three equal parts, transfer to new small EP tubes, place in a PCR instrument, and heat treat at 40℃, 44℃ and 48℃ for 3min respectively.
[0044] ⑤ Place the heat-treated cell suspension in liquid nitrogen and freeze and thaw repeatedly three times, place it in a 4°C constant temperature centrifuge, centrifuge at 13000 rpm for 18 minutes, and collect the supernatant as the protein.
[0045] ⑥ Add 50 μL of 2×SDS loading buffer without mercaptoethanol to the supernatant protein solution, incubate at 99°C for 10 min, and detect the expression of UBE2N protein by Western Blot experiment.
[0046] The results are as follows Figure 3 As shown, the results of cell thermal shift assay (CETSA) showed that with the increase of temperature, the expression of UBE2N protein in the cells treated with tripterygium wilfordii was significantly higher than that in the control group, indicating that tripterygium wilfordii inhibited the degradation of UBE2N protein and significantly improved the thermal stability of UBE2N protein; considering that when the target protein binds to the drug molecule, the target protein usually becomes stable and is not prone to thermal denaturation and degradation, our results show that tripterygium wilfordii targeted the UBE2N protein.
[0047] Example 2: Tripterygium wilfordii inhibits the activity of UBE2N
[0048] In vitro ubiquitination assay to analyze the inhibitory effect of tripterygium wilfordii on UBE2N activity:
[0049] (1) Take three small PCR tubes, number them ①②③ respectively, and add 2.5 μM UBE2N protein to each tube, with a final concentration of 2.5 μM.
[0050] (2) Add tripterygium wilfordii alkaloids (final concentration 50 μM) to tube ①, and add corresponding control solvents to tubes ② and ③; incubate at room temperature for 30 min.
[0051] (3) Add 5 μL 10×Ubiquitinylation buffer, 20 U / mL IPP solution, 1 mM DTT, 5 mM Mg-ATP, 0.1 μM E1 and 2.5 μM Ub to tubes ① and ②; add 5 μL 10×Ubiquitinylation buffer, 20 U / ml IPP solution, 1 mM DTT, 0.1 μM E1 and 2.5 μM Ub to tube ③; make up the reagents in the three PCR tubes to 50 μL with deionized water.
[0052] (4) Place tubes ①, ② and ③ in a 37°C incubator and incubate for 4 hours.
[0053] (5) Add 50 μL of 2× non-reducing SDS loading buffer to each tube to terminate the reaction.
[0054] (6) The expression levels of UBE2N-Ub in the three groups of samples were detected by western blot experiment.
[0055] like Figure 4 As shown, treatment with tripterygium wilfordii can significantly weaken the expression of UBE2N-Ub protein, that is, weaken the binding effect of UBE2N with Ub, indicating that tripterygium wilfordii can inhibit the catalytic activity of UBE2N protein.
[0056] Example 3: Tripterygium wilfordii alkaloids inhibit chemotherapy resistance of lung cancer cells in vitro
[0057] (1) Waiting for A549 CDDP When the cells (purchased from Shanghai Fuheng Biotechnology Co., Ltd.) were in good growth condition, they were washed once with PBS and 500 μL of trypsin was added to digest the cells;
[0058] (2) Dilute the cells to 3.0×10 4 / mL, pipette evenly;
[0059] (3) A sterile 96-well plate was prepared and set up for the cisplatin (CDDP) (0, 0.4, 0.8, 1.6, 2.4, 3.2, 4, 4.8, 5.6, 6.4, 7.2, 8, 8.8, 9.6, 10.4, 11.2 and 12 μg / mL) + Vehicle (DMSO) treatment group and the cisplatin (0, 0.4, 0.8, 1.6, 2.4, 3.2, 4, 4.8, 5.6, 6.4, 7.2, 8, 8.8, 9.6, 10.4, 11.2 and 12 μg / mL) + tripterygium wilfordii (50 μM) combined treatment group, with three replicate wells in each group. 100 μL of the diluted cell suspension was added to each well and the plate was cultured in a 37°C, 5% CO2 incubator;
[0060] (4) After the cells adhered, they were treated with cisplatin alone or cisplatin + tripterygium wilfordii alkaloids, respectively, and placed in a constant temperature incubator at 37°C and 5% CO2 for 48 h;
[0061] (5) Discard the supernatant culture medium in all wells, add 100 μL of fresh complete culture medium and 10 μL of CCK-8 reagent, place in a 37°C constant temperature incubator, culture for 2 h under 5% CO2 conditions, and then detect the absorbance value with an enzyme reader;
[0062] (6) Based on the absorbance value, draw an IC50 curve and analyze the IC50 value.
[0063] like Figure 5 As shown, compared with the control group, the A549 CDDP The IC50 value of cisplatin in cells was significantly reduced, indicating that triptolide can significantly inhibit the chemotherapy resistance of lung cancer in vitro.
[0064] Example 4: Tripterygium wilfordii alkaloids inhibit chemotherapy resistance in lung cancer in vivo
[0065] (1) Select 6-8 week old male NOD-SCID nude mice, weighing 18-20 g, 5 mice per group. 6 / Number, inoculated with human lung cancer cell A549 CDDP ;
[0066] (2) Ten days after cell inoculation, mice were intraperitoneally administered every other day with a control solvent, normal saline, as a control group (Vehicle), 3 mg / kg cisplatin as a cisplatin-only treatment group (CDDP), 50 mg / kg Wilforine, and 3 mg / kg cisplatin (CDDP) + 50 mg / kg Wilforine combined treatment according to the body weight of nude mice;
[0067] (3) Two weeks after administration, the nude mice were sacrificed, the tumors were photographed, and statistical analysis was performed;
[0068] like Figure 6 As shown, compared with the group treated with cisplatin (CDDP) alone, tripterygium wilfordii alkaloids combined with cisplatin (CDDP) treatment can significantly inhibit the tumor volume of mice, indicating that tripterygium wilfordii alkaloids inhibit lung cancer chemotherapy resistance in vivo.
[0069] Example 5: Tripterygium wilfordii alkaloids inhibit lung cancer metastasis in vitro
[0070] (1) Waiting for A549 CDDP When the cells are growing well, wash them once with PBS and add trypsin to digest the cells;
[0071] (2) Dilute the cells to 5.0×10 5 / mL, pipette evenly;
[0072] (3) Take a sterile 24-well plate, add 500 μL of complete culture medium to each well, place the Transwell chamber in the well, and add 200 μL of diluted cell suspension to each chamber;
[0073] (4) The cells were treated with triptolide (final concentration of 50 μM) and an equal volume of control solvent DMSO (Vehicle), and cultured in a 37°C constant temperature incubator with 5% CO2 for 10 h;
[0074] (5) Remove the chamber, wash it twice in PBS solution, and wipe off the cells inside the chamber with a cotton swab;
[0075] (5) Place the chamber in crystal violet staining solution for 3 h, remove the chamber, wash it 2 to 3 times in PBS solution, and place it in a clean 24-well plate;
[0076] (6) The images of cell migration in the Transwel chamber were collected under a microscope, and then the cell migration was analyzed using Image J software.
[0077] like Figure 7 As shown, compared with the control group, the number of cells passing through the chamber in the group treated with tripterygium wilfordii was significantly reduced, indicating that tripterygium wilfordii can inhibit the metastasis of lung cancer in vitro.
[0078] Example 6: Tripterygium wilfordii alkaloids inhibit lung cancer metastasis in vivo
[0079] (1) Select 6-8 week old male nude mice, 5 mice per group. 6 / number, inoculated with human lung cancer A549 cells by tail vein injection CDDP ;
[0080] (2) After cell inoculation, cells were treated with the control solvent DMSO (Vehicle) and triptolide (50 mg / kg) by intraperitoneal administration every other day;
[0081] (3) Eight weeks after administration, the nude mice were killed, and the lung tissues of the nude mice were observed and photographed, and statistical analysis was performed; Figure 8 As shown, compared with the control group, the number of lung tumor metastases in the mice treated with tripterygium wilfordii was significantly reduced, indicating that tripterygium wilfordii can inhibit lung cancer metastasis in vivo.
[0082] Although the preferred embodiments of the present invention have been described, those skilled in the art may make other changes and modifications to these embodiments once they have learned the basic creative concept. Therefore, the appended claims are intended to be interpreted as including the preferred embodiments and all changes and modifications that fall within the scope of the present invention.
[0083] Obviously, those skilled in the art can make various changes and modifications to the present invention without departing from the spirit and scope of the present invention. Thus, if these modifications and variations of the present invention fall within the scope of the claims of the present invention and their equivalents, the present invention is also intended to include these modifications and variations.
Claims
1. Use of triptolide or its derivatives in the preparation of inhibitors of ubiquitin-binding enzyme UBE2N.
2. An inhibitor of ubiquitin-binding enzyme UBE2N, characterized in that The triptolide or its derivatives as described in claim 1 are the only active ingredients.
3. The inhibitor of ubiquitin-binding enzyme UBE2N according to claim 2, characterized in that Also includes: Pharmaceutically acceptable excipients.
4. The inhibitor of ubiquitin-binding enzyme UBE2N according to claim 3, characterized in that The mass fraction of the tripterygium wilfordii alkaloid is 1 w% to 99 w%.
5. The inhibitor of ubiquitin-binding enzyme UBE2N according to claim 3, characterized in that The auxiliary materials are selected from one or more of propellants, solubilizers, cosolvents, emulsifiers, colorants, adhesives, disintegrants, fillers, lubricants, wetting agents, osmotic pressure regulators, stabilizers, glidants, flavoring agents, preservatives, suspending agents, coating materials, fragrances, anti-adhesive agents, integrities, penetration enhancers, pH regulators, buffers, plasticizers, surfactants, foaming agents, defoamers, thickeners, inclusion agents, humectants, absorbents, diluents, flocculants and deflocculating agents, filter aids and release retardants.
6. Use of the inhibitor of ubiquitin-binding enzyme UBE2N as claimed in claim 2 in the preparation of a drug for treating lung cancer.
7. The use according to claim 5, characterized in that The inhibitor of the ubiquitin-binding enzyme UBE2N is used to promote the sensitivity of lung cancer-resistant cells to platinum-based chemotherapy drugs.
8. The use according to claim 7, characterized in that The platinum chemotherapy drugs include cisplatin.
9. The use according to claim 5, characterized in that The lung cancer includes lung squamous cell carcinoma, small cell lung cancer, lung adenocarcinoma, lung adenosquamous carcinoma or lung carcinoid.
10. A drug for treating lung cancer, characterized in that: include: The inhibitor of ubiquitin-binding enzyme UBE2N as claimed in claim 2.
Citation Information
Patent Citations
Preparation method of triptolide and ramification composition thereof
CN103159822A
Application of compounds in preparation of drugs for treating multi-drug resistant cancers
CN110787173A
Method for screening drug resistant reversion agent for multiple drugs of treating tumors mediated by protein group of anti transportation
CN1661040A
